Niramai announces ‘Easy Launch kits’ for NGOs to enable Community Screening

Bengaluru, 28th September, 2022: Niramai, the innovative health-tech Indian company which has developed the world-renowned radiation-free, automated and non-invasive breast cancer screening test has launched a new initiative in the October Breast Cancer Awareness Month. Now, community healthcare providers, NGOs and public health workers who are conducting health awareness talks can also perform screening camps in conjunction. This new initiative offers “Easy Launch Kits” for breast cancer screening as a special ‘Starter Kit’ for socially concerned organizations enabling them to provide accurate breast cancer screening services by spending just Rs 1000 per day. This kit enables partner cancer societies, hospitals, diagnostic centers, and NGOs to provide Niramai’s automated breast cancer screening service for unlimited monthly screenings to triage population and identify patients with high suspicion of breast malignancy. This limited period offer with bookings available from 1st – 31st October on ‘First come first serve basis’, will help screenings become accessible and affordable to more women.

Dr. Geetha Manjunath, CEO & Founder, Niramai, said, “It is extremely crucial to encourage more and more women to get screened every year to enable early-stage detection and early treatment intervention which not only save lives but also reduces treatment costs. Early-stage detection makes the person go back to normal life very soon. Since our test provides a “changing room” experience where nobody sees or touches the women during the test, we have so far received excellent feedback from both urban and rural women. There are many socially concerned organizations who actually have similar mission of detecting cancer early, but they were unable to provide free screening services due to the exorbitant costs of hiring a mobile mammography van. With the launch of our Starter Kit, we are enabling a collaborative platform to make screenings accessible and scalable to save thousands of women.  ”

Niramai has been at the forefront of bringing safe, economical, and accessible screening solutions to women across age groups and sections of the society. With this launch, Niramai hopes to impact the lives of more women positively by encouraging them to go for screenings at their nearest diagnostic center, hospital or NGO. Niramai has partnered with reputed healthcare providers such as Apollo Clinics, HCG hospitals, Medall Diagnostics, Rainbow Hospital and Medanta and more, to provide the novel breast cancer screening solution in their facility as well as conduct outreach programs in apartment complex

Niramai has also launched a free whatsapp chatbot for urban women on +91 94834 34444. This is a free “breast health help line” where women can ask any questions related to breast health and evaluate their risk to breast cancer using a validated Machine-Learning-based risk assessment service called with a easy and user-friendly interface through Niramai’s ChatBot. This online assessment test takes only a few minutes and the results are provided within minutes.

Niramai has conducted over 70,000 screenings in India and is operational in over 150 installations at hospitals and diagnostic centres across 29 Indian cities. Niramai also launched Home Screenings service in collaboration with Healthians, Apollo, MiyaraWomen, ProactiveForHer and others.  Niramai has also started international commercial activity in Kenya, UAE, Turkey, UK, Switzerland, Sweden and USA. Niramai is the 1st Indian startup in the female healthcare space to have received regulatory approval from two major global regulatory bodies – the US FDA clearance and the European CE Mark Approval.

Read More

Niramai gets US FDA clearance for their first medical device, SMILE-100 System

US markets now open for the Innovative Indian Startup

Bengaluru, 14 March, 2022: Niramai Health Analytix, the deep-tech Bangalore-based healthcare company offering a novel radiation-free, non-touch, accurate, breast cancer screening solution in India, has now received US FDA clearance for their first device called SMILE-100 System. The SMILE-100 System is a breast thermography device that helps a healthcare personnel to review, measure and analyze thermally significant indications in the breast region. It can be used in the hospital, acute care settings, outpatient surgery, healthcare practitioner facilities or an environment where patient care is provided by qualified healthcare personnel. It is intended for use as adjunctive diagnostic imaging for thermally significant indications in the breast region.  

The SMILE-100 System assists experts to visualize high thermal activity patterns clearly demarcated on thermal images as hotspots and can enable healthcare professionals to make better decisions in breast cancer screening and diagnosis.  Another unique feature of SMILE-100 is use of their patented artificial intelligence-based algorithms to check the quality of input thermal images, which can greatly reduce the errors in thermal image capture and enable low skilled health workers to confidently perform the imaging. 

Dr. Geetha Manjunath, CEO and Founder of Niramai, said, “We are super excited to announce the FDA 510(k) clearance of SMILE-100 System. A proud moment for the team. It was a great learning experience to go through the very rigorous US regulatory process. This win further validates the intrinsic power of NIRAMAI team and has given us the confidence that we can build many more such world-class medical devices of high quality and help reduce untimely deaths due to cancer.”

Niramai is a pioneer in the breast cancer screening with 26 granted international patents. An US FDA approved device is a marquee asset for any Indian health-tech company. In fact, Niramai is the first Indian company to get an US FDA clearance for a medical device used for women health. Last year, the company announced European CE approval for their Thermalytix™ Solution and have already started pilots in multiple European countries. This FDA approval will now give Niramai a tool to foray into the US market and beyond.

Dr Kiran Mazumdar Shaw, the global biotech business leader and Biocon chairperson appreciated this news and said “I congratulate Geetha and her team for this tremendous achievement. Niramai is one of the very few deeptech startups from India which has obtained both European and US clearance for their innovative medical device. Indian startups are solving important healthcare problems that is the need of the hour today. Such milestones of innovation showcase the power of Indian women-led companies to the rest of the world”.

Mr. Manish Singhal, Founding Partner of pi Ventures and the lead investor of Niramai who has been part of their journey since 2017, commented, “In the last five years, we have seen Niramai grow in every aspect – product innovation, team strength, clinical provenance, product adoption and international recognition. I congratulate the team for this exciting win of the FDA clearance for their SMILE-100 System. It’s a great feat for any Indian Startup to get US approval for their medical device. This can be the key inflection point for the company to take their product truly global saving lives all the world.”

NIRAMAI has now created its own reputed brand in India with their innovative breast health products.  Partnering with experienced radiologists and reputed hospital / diagnostic chains in India such as Apollo Clinics, HCG Cancer Hospitals, Rainbow Hospitals among others, Niramai provides breast screening services across 19 cities in India.  Niramai also conducts large scale screening camps in association with Karnataka Cancer Society, Rotary International and other socially concerned organizations. With the FDA cleared SMILE-100 System and CE approved Thermalytix products, the company is now taking their Made-in-India innovation to global scale.


About Niramai Health Analytix:

NIRAMAI Health Analytix is a deep-tech healthcare company offering a novel Artificial Intelligence-based devices. Their flagship product is Thermalytix which is radiation-free, non-touch, accurate, breast cancer screening test for women of all age groups. The solution is portable, automated and detects breast cancer at a much earlier stage than traditional screening methods. NIRAMAI was co-founded in July 2016 by Dr. Geetha Manjunath and Ms Nidhi Mathur. NIRAMAI has so far raised a total of $7M from institutional investors from India, Japan and Singapore. Investors include Dream Incubator, BeeNext, pi Ventures, Ankur Capital, Axilor Ventures, 500 Startups, and others.  NIRAMAI has won many international prestigious awards including World Bank instituted Global Women HealthTech Award 2022, National Startup Award 2020 in India, the Gold prize in Hack Osaka 2019 in Japan and and have received research funding from the Bill & Melinda Gates Foundation and CDC UK. Niramai also conducts regular free webinars and awareness talks on breast health and provides a free breast health helpline on Whatsapp number on +91-9483434444.

Read More

Niramai receives CE Mark – Regulatory approval for Europe

Bengaluru-based healthtech startup Niramai Health Analytix’s patented, radiation-free breast cancer screening solution, Thermalytix®, has received CE mark approval, ISO 13485, and MDSAP (Medical Device Single Audit Programme) International Certifications.

Read more at:

Read More